Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216654 | 0.87 | TLR2 (0.37) | TLR2ROCK2PRKACAAKT3ALB | |
| SCHEMBL12227120 | 0.81 | NOD1 (0.44) | TLR2ROCK2PRKACAAKT3ALB | |
| SCHEMBL24592963 | 0.80 | SIRT5 (0.47) | TLR2ROCK2PRKACAAKT3NOD1 | |
| SCHEMBL25026533 | 0.79 | NOD1 (0.41) | ROCK2PRKACAAKT3ALBNOD1 | |
| SCHEMBL31384213 | 0.76 | NOD1 (0.52) | ALBNOD1 | |
| SCHEMBL31384226 | 0.76 | NOD1 (0.41) | ALBNOD1 | |
| SCHEMBL27037078 | 0.76 | ROCK2 (0.33) | TLR2ROCK2PRKACAAKT3NOD1 | |
| SCHEMBL24630046 | 0.76 | NOD1 (0.48) | ALBNOD1SLC6A5 | |
| SCHEMBL29072117 | 0.76 | NOD1 (0.48) | ALBNOD1SLC6A5 | |
| SCHEMBL29072118 | 0.76 | NOD1 (0.48) | ALBNOD1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786576-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786576-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | TLR2 373/4885ROCK2 1248/4885PRKACA 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.